Results 191 to 200 of about 595,828 (287)

A Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still's Disease‐like Autoinflammatory Syndrome

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Still's Disease represents a prototypical polygenic systemic autoinflammatory diseases (SAIDs), characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still's disease remains unreported.
Longfang Chen   +23 more
wiley   +1 more source

Comparative Evaluation of Tissue and Systemic Responses to Electrospun Biodegradable Polymer and Polypropylene Implants Using hs-CRP and Immunohistochemical Markers. [PDF]

open access: yesInt J Mol Sci
Eisenach IA   +7 more
europepmc   +1 more source

Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data

open access: yesArthritis &Rheumatology, EarlyView.
Objective Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA.
Manar Elsayed   +11 more
wiley   +1 more source

Interleukin‐2 deprived state of regulatory T cells and their recovery by low‐dose interleukin‐2 in patients with inflammatory myopathies

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Regeneration and expansion of regulatory T cells (Treg) by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg‐IL‐2 axis emerge in ...
Justus Ohmes   +10 more
wiley   +1 more source

Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK‐pot Collaboration

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To develop, externally validate, and simplify a machine‐learning (ML) model to predict remission between six and 24 months in rheumatoid arthritis (RA) patients initiating TNF inhibitors, JAK inhibitors, IL‐6 inhibitors, abatacept, or rituximab, using data from 11 international registries in the JAK‐pot collaboration.
Zubeyir Salis   +22 more
wiley   +1 more source

Inferring rheumatoid arthritis disease activity status from the electronic health records across health systems

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Disease activity plays a central role in rheumatoid arthritis (RA) clinical studies. The inconsistent availability of data on disease activity in real‐world electronic health records (EHR) data has limited the ability to generate real‐world evidence (RWE). This study aimed to develop and validate scalable machine learning (ML) models to infer
David Cheng   +34 more
wiley   +1 more source

Home - About - Disclaimer - Privacy